EGFR-driven lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and...

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Immunotherapies show limited efficacy in EGFR-driven lung adenocarcinoma (LUAD).
• Understanding local immunosuppression mechanisms is crucial for developing new therapies.
• Tumor-associated alveolar macrophages (TA-AMs) play a role in tumor growth and immune evasion.

Purpose of the Study:

• To investigate the mechanisms by which TA-AMs support EGFR-driven LUAD growth.
• To identify therapeutic targets for overcoming immunotherapy resistance in LUAD.
• To elucidate the role of GM-CSF and PPARγ signaling in TA-AM function and LUAD progression.

Main Methods:

• Analysis of macrophage proliferation and function in response to epithelial secretions.
• Inhibition of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Peroxisome Proliferator-Activated Receptor gamma (PPARγ) signaling.
• Assessment of cholesterol metabolism and EGFR phosphorylation in LUAD cells.
• Evaluation of combined therapies including PPARγ inhibition and statins.

Main Results:

• Elevated surfactant and GM-CSF induce TA-AM proliferation, supporting LUAD growth.
• GM-CSF-PPARγ signaling in TA-AMs promotes cholesterol efflux to tumor cells.
• Inhibiting airway GM-CSF or PPARγ in TA-AMs impairs cholesterol metabolism and restrains LUAD progression.
• Combined blockade of PPARγ in TA-AMs and statin therapy suppressed tumor progression and enhanced anti-tumor immunity.

Conclusions:

• Cancer cells metabolically co-opt TA-AMs via GM-CSF-PPARγ signaling for nutrient supply.
• This interaction promotes oncogenic signaling and growth in EGFR-mutant LUAD.
• Targeting the GM-CSF-PPARγ axis in TA-AMs presents a promising therapeutic strategy for immunotherapy-resistant LUAD.